Specialist and experienced pricing and market access consultancy
We will develop and implement a successful launch strategy for your product.
We build payer focussed pricing and market access strategies to enable commercial success.
We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.
Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.
Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.
Individual solutions to suit you
We adapt our working style to reflect your needs
We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies
We react quickly and effectively to provide the best support possible
Achieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden…
Read moreThe recent appraisal by the National Institute for Health and Care Excellence (NICE) for Iptacopan, …
Read moreWe’re thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona …
Read moreWe’re delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We’ll…
Read moreIntroduction What is the secret to a successful drug launch? One crucial factor is establishing a cr…
Read moreDespite positive outcomes in treating Alzheimer’s disease, NICE cites small benefits and high costs …
Read moreThis research leverages RWE using a quality-by-design (QbD) framework for proactive risk surveillanc…
Read moreWe explore whether pharma and biotech manufacturers are ready for the new EU HTA process and what op…
Read moreWe explore how the integration of real-world data can revolutionise clinical decision support system…
Read more